Cell Therapy Development Services

Cell therapy for brain tumors utilizes the body's immune system, including engineered T cells and dendritic cells, to precisely target and eliminate tumor cells while preserving healthy tissue. Alfa Cytology provides cell therapy for brain tumors, offering innovative strategies to enhance the effectiveness of T-cell and dendritic cell-based treatments.

Introduction to Cell Therapy for Brain Tumors

Cell therapy is a promising approach for treating brain tumors by harnessing the body's immune system to target and destroy cancer cells. This therapy involves enhancing or engineering immune cells, such as T cells, dendritic cells, or natural killer (NK) cells, to recognize and attack tumor-specific antigens. Techniques like chimeric antigen receptor (CAR) T-cell therapy and dendritic cell vaccines have shown potential in improving treatment outcomes. By stimulating a targeted immune response, immune cell therapy offers a novel and personalized strategy to combat brain tumors while minimizing damage to healthy tissues.

Fig 1. A schematic of CAR T targeting brain tumors. (LIN Y J, et al., 2022)

Cell Therapy Development for Brain Tumors

Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Leveraging our advanced immune cell engineering technology platform, Alfa Cytology specializes in assisting clients in developing brain tumor cellular therapies. We focus on the infiltration and targeted killing mechanisms of treatments such as CAR-T and TILs within the brain tumor microenvironment. With extensive preclinical experimental experience, we utilize multi-omics analysis and bioinformatics modeling to precisely optimize immune cell functions.

Cell Therapy for Brain Tumors

IL Therapy for Brain Tumors

Alfa Cytology develops personalized therapies based on tumor-infiltrating lymphocytes (TILs). These TILs are expanded and activated in vitro to enhance their ability to penetrate the blood-brain barrier and target the heterogeneous antigens of gliomas.

CAR T-cell Therapy for Brain Tumors

We use gene-editing technology to construct CAR-T cells targeting brain tumor-specific antigens like EGFRvIII and IL13Rα2. Combining this with local delivery or chemokine modification strategies, we aim to overcome the immunosuppressive microenvironment and enhance targeting and killing efficiency against solid tumors.

TCR Therapy for Brain Tumors

Using single-cell sequencing and AI-based epitope prediction, we are screening for tumor neoantigen-specific T-cell receptor (TCR) sequences. Alfa Cytology optimizes T-cell affinity and safety to address the issue of low immunogenicity in brain tumors.

NK-CIK Cell Therapy for Brain Tumors

By combining natural killer (NK) cells and cytokine-induced killer (CIK) cells, we aim to eliminate brain tumor stem cells through multi-target synergistic action. We enhance cell proliferation and infiltration abilities by incorporating cytokines such as IL-15 and IL-21, thereby reducing the risk of recurrence.

Dendritic Cell Therapy for Brain Tumors

Dendritic cell therapy for brain tumors involves utilizing autologous dendritic cells (DCs) loaded with tumor antigens to activate specific T-cell responses. To establish systemic anti-tumor immune memory, we enhance the efficiency of intracerebral delivery of these antigens through nanocarrier systems or focused ultrasound technology.

Alfa Cytology specializes in assisting clients with the development of brain tumor immune cell therapies. With a wealth of experience, we have supported numerous preclinical research projects for CAR-T and TCR-T therapies. If you are facing challenges in developing brain tumor immune cell therapies, please do not hesitate to contact our technical team for customized solutions.

Reference

1. LIN Y J, MASHOUF L A, LIM M. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future [J]. Frontiers in immunology, 2022, 13: 817296.